Zebrafish Lipid Metabolism Assay for Drug Screening

Information

  • Research Project
  • 6833594
  • ApplicationId
    6833594
  • Core Project Number
    R44DK064472
  • Full Project Number
    2R44DK064472-02
  • Serial Number
    64472
  • FOA Number
    PA-01-93
  • Sub Project Id
  • Project Start Date
    6/15/2003 - 21 years ago
  • Project End Date
    8/31/2007 - 17 years ago
  • Program Officer Name
    DENSMORE, CHRISTINE L.
  • Budget Start Date
    9/30/2004 - 20 years ago
  • Budget End Date
    8/31/2005 - 19 years ago
  • Fiscal Year
    2004
  • Support Year
    2
  • Suffix
  • Award Notice Date
    9/30/2004 - 20 years ago
Organizations

Zebrafish Lipid Metabolism Assay for Drug Screening

DESCRIPTION (provided by applicant): Cardiovascular disease is the number one cause of death in the United States today. High levels of cholesterol and triglycerides have been identified as major contributing factors to heart disease. Furthermore, lipid-lowering drugs such as statins and fibrates have been shown to reduce the incidence of coronary disease. Although current drugs have enjoyed some success in this area, a need remains for improved drugs with fewer side effects. The goal of this proposal is to develop a fluorescent zebrafish assay (Z-Lipotrack) to identify new drugs for lipid management. The zebrafish has many advantages to model vertebrate diseases. In particular, they process lipids through the digestive system in a manner similar to mammals. Because zebrafish larvae are essentially transparent, such processing can be readily observed in the whole organism, with the aid of fluorescent lipid substrates, which are swallowed by the zebrafish larvae and transported from the intestine to the liver and gall bladder. To increase the usefulness of Z-Lipotrack for high throughput drug screening, a fluorescent plate reader will be developed to automatically image the Z-Lipotrack assay. Secondly, the use of Z-Lipotrack for compound optimization will be evaluated. Finally, compounds identified as potential lipid-lowering drugs in Phase 1will be fully characterized and optimized through the use of medicinal chemistry to identify lead compounds for further animal and human studies.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    645969
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:645969\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ZYGOGEN, LLC
  • Organization Department
  • Organization DUNS
    028796170
  • Organization City
    ATLANTA
  • Organization State
    GA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    30303
  • Organization District
    UNITED STATES